Clinical Focus

  • Hospice and Palliative Medicine
  • Clinics, Outpatient
  • Hospice Care

Academic Appointments

Administrative Appointments

  • Associate medical director, VITAS Healthcare (2013 - Present)

Honors & Awards

  • VITAS BEST Award, VITAS Healtchare (2014)
  • VITAS Leadership Council Award for Outstanding Team Physician, VITAS Healthcare (2012)
  • Member, Alpha Omega Alpha Medical Honor Society (2006-present)

Boards, Advisory Committees, Professional Organizations

  • Member, ABIM SEP Committee for Hospice and Palliative Medicine (2014 - 2016)

Professional Education

  • Residency: Stanford University Hospital and Clinics (2009) CA
  • Board Certification: American Board of Internal Medicine, Hospice and Palliative Medicine (2010)
  • Fellowship: VA Medical Center Palo Alto (2010) CA
  • Medical Education: Oregon Health Science University (2006) OR

Graduate and Fellowship Programs

  • Hospice & Palliative Medicine (Fellowship Program)

All Publications

  • Dronabinol for the Treatment of Paraneoplastic Night Sweats in Cancer Patients: A Report of Five Cases. Journal of palliative medicine Carr, C., Vertelney, H., Fronk, J., Trieu, S. 2019


    BACKGROUND: Night sweats significantly impact the quality of life for cancer patients and are often resistant to treatment. Cannabinoids have been shown to modulate cytokine activity and produce hypothermia in animal models, suggesting that they may be a promising candidate for palliation of night sweats in patients with oncologic disease.OBJECTIVE: Assess efficacy of the oral cannabinoid, dronabinol, for palliation of night sweats in cancer patients.DESIGN: A retrospective record search identified five cancer patients who had tried oral dronabinol for palliation of their night sweats between 2013 and 2016 and subjectively reported on its efficacy.SETTING/SUBJECTS: A convenience sample of five patients from the outpatient consultative palliative medicine program at Stanford Medical Center was chosen from a search of past records. Patients were included if they had a cancer diagnosis and complained of night sweats that subjectively interfered with their quality of life. All agreed to try oral dronabinol for palliation of their night sweats.MEASUREMENTS: Patients self-reported the effect of oral synthetic dronabinol on their night sweats.RESULTS: Treatment of five patients with advanced cancer with synthetic orally administered dronabinol resulted in the successful management of persistent symptomatic paraneoplastic night sweats.CONCLUSION: Dronabinol and/or medicinal cannabis are promising therapies for palliation of night sweats in cancer patients.

    View details for PubMedID 30759037

  • PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., Harman, S., Dwyer, P., Bosch, J., Shaw, H., Safari, S., Oden, R., Morrison, T., Blayney, D. LIPPINCOTT WILLIAMS & WILKINS. 2013: S1324
  • Outpatient palliative care at a tertiary cancer center: Perceptions, pathways, and pitfalls Ramchandran, K., Trieu, S., Harman, S., Passaglia, J., Rodriguez, J., Dwyer, P., Oden, R. AMER SOC CLINICAL ONCOLOGY. 2012
  • Malignancy in the Setting of the Anti-Synthetase Syndrome JCR-JOURNAL OF CLINICAL RHEUMATOLOGY Rozelle, A., Trieu, S., Chung, L. 2008; 14 (5): 285-288


    Malignancy and interstitial lung disease (ILD) are 2 conditions associated with dermatomyositis (DM) that are responsible for a significant portion of the morbidity and mortality related to this disease; however, they rarely occur in the same patient. The antisynthetase syndrome consists of several characteristics, including ILD, arthritis, Raynaud phenomenon, "mechanic's hands," and positive antibodies to tRNA synthetases, which have each been negatively associated with cancer. When patients with DM present with such characteristics, clinicians may be falsely reassured that a thorough malignancy screen is unnecessary. We describe a patient who presented with the antisynthetase syndrome and was subsequently found to have colon cancer. Removal of the cancer led to resolution of the myositis and lung disease, but the patient's rash and arthritis persisted and ultimately required immunosuppressive therapy. We provide a review of the literature describing the concurrence of both this syndrome and ILD alone, with malignancy. We conclude that a thorough and expedited age-appropriate malignancy work up is indicated in all patients with a new diagnosis of DM, despite the presence of disease characteristics that are usually not associated with cancer.

    View details for DOI 10.1097/RHU.0b013e31817d116f

    View details for Web of Science ID 000260154000008

    View details for PubMedID 18664993